ライフサイエンスコーパス: prostate-specific antigen

1 urine doped with different concentrations of prostate specific antigen.

2 amino acids sequence (HSSKLQL) specific for Prostate Specific Antigen.

3 pairs that are associated with pre-operative prostate-specific antigen.

4 ction and prostate cancer together with KLK3/prostate-specific antigen.

5 on of PSMA PET-derived parameters with serum prostate-specific antigen.

6 te-specific antigen < 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL), LDR brachyth

7 /X M0, 25% N0M0; 94% newly diagnosed; median prostate-specific antigen, 66 ng/mL.

8 negatively correlated with the expression of prostate-specific antigen, a marker of AR signaling.

9 ould improve specificity over measurement of prostate-specific antigen alone for detecting cancer wit

10 o biopsy, adjusting for age and longitudinal prostate-specific antigen and digital rectal examination

11 cancer screening currently consists of serum prostate-specific antigen and digital rectal examination

12 ide, 25-hydroxyvitamin D) and 2 nonhormones (prostate-specific antigen and ferritin).

13 Prostate-specific antigen and prostate-specific membrane

14 o noted a significant decrease in both KLK3 (prostate-specific antigen ) and FOLH1 (prostate-specific

15 variate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal e

16 rkers, including human alpha-thrombin, human prostate specific antigen, and human epidermal growth fa

17 performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than whi

18 lation with progression-free survival (PFS), prostate-specific antigen, and markers of bone turnover.

19 ety; progression-free survival (PFS); tumor, prostate-specific antigen, and pain response; pharmacoki

20 ical distress, cancer-specific distress, and prostate-specific antigen anxiety.

21 t prostate cancers after the introduction of prostate-specific antigen-based screening are now being

22 d indices and explored their relation to the prostate-specific antigen blood value, the bone scan ind

23 ional imaging and unspecific fluctuations in prostate-specific antigen can hamper early diagnosis of

24 SUVs and lesion number were correlated with prostate-specific antigen change, clinical impression, a

25 ad not had radiotherapy using Gleason score, prostate-specific antigen concentration, surgical margin

26 e and that anti-GRP78 AutoAb levels parallel prostate-specific antigen concentrations in patient-deri

27 Men with prostate-specific antigen concentrations up to 15 ng/mL,

28 acy was biochemical response as defined by a prostate-specific antigen decline >/= 50% from baseline

29 Both patients experienced a prostate-specific antigen decline to below the measurabl

30 At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, bu

31 4; P = .030), but not when also adjusted for prostate-specific antigen density (PSAD; HR, 1.85; 95% C

32 cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination pro

33 Randomisation was stratified by prostate-specific antigen doubling time and baseline use

34 , castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or

35 , castration-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 mont

36 C at high risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but

37 Transmission SPR measurements of free prostate specific antigen (f-PSA), which is similar in s

38 were performed in 36 subjects with a rising prostate-specific antigen for known (n = 15) or suspecte

39 device and tested for the detection of free Prostate Specific Antigen (fPSA).

40 the MRI grade model and clinical parameters (prostate-specific antigen, Gleason score) for pathologic

41 r and had received no previous chemotherapy; prostate-specific antigen greater than 5 ng/mL; and a Ka

42 application of this technology in detecting Prostate Specific Antigen in clinically relevant levels

43 tor, aedemonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and an

44 We demonstrate femtomolar-level detection of prostate-specific antigen in biological fluids, as well

45 tures plus the MRI-based EPE grading system (prostate-specific antigen, International Society of Urol

46 n LNCaP cell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression.

47 , or placebo (Arm P; n = 433), stratified by prostate-specific antigen (less than 50 ng/mL v 50 ng/mL

48 Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increas

49 tectomy and/or radiation therapy with rising prostate-specific antigen level (median, 2.27 ng/mL; ran

50 ing hemoglobin level (r = -0.521, P < .001), prostate-specific antigen level (r = 0.556, P < .001), l

51 ), Gleason score (rho, range, 0.03 to 0.20), prostate-specific antigen level (rho, range, -0.07 to 0.

52 changes in tDV and best percentage change in prostate-specific antigen level and circulating tumor ce

53 st and logistic regression; correlation with prostate-specific antigen level and circulating tumor ce

54 The median prostate-specific antigen level at imaging and number of

55 cancer is suspected when an increase in the prostate-specific antigen level is detected after radica

56 tile range [IQR], 61-72) years, median (IQR) prostate-specific antigen level of 43 (18-88) ng/mL.

57 ; they had Gleason scores of 7-10 and a mean prostate-specific antigen level of 7.8 mug/L (range, 5.4

58 e prostate cancer, particularly those with a prostate-specific antigen level of less than 10 ng/mL an

59 alliative radiotherapy, and the median (IQR) prostate-specific antigen level was 146 (51-354).

60 66-74 y) with biochemical recurrence (median prostate-specific antigen level, 1.31 ng/mL; interquarti

61 Eighty-three patients were eligible (median prostate-specific antigen level, 1.9 ng/mL).

62 with prostate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL; range, 0.25-29

63 Methods: Twenty-one patients (prostate-specific antigen level, 7.4 +/- 6.8 ng/mL) with

64 Serum prostate-specific antigen level, digital rectal examinat

65 Hypofractionation, pretreatment prostate-specific antigen level, Gleason score, and clin

66 ) and metastatic findings were compared with prostate-specific antigen level, International Society o

67 (244/691) and was associated with increasing prostate-specific antigen level, ISUP grade, and clinica

68 At multivariate analysis, prostate-specific antigen level, primary Gleason grade g

69 number of ADC treatment cycles, or change in prostate-specific antigen level.

70 ve study of 140 patients with elevated serum prostate specific antigen levels and/or abnormal digital

71 -targeted radiotracers than fluciclovine for prostate specific antigen levels of 1.0-1.9 ng/mL.

72 gital rectal examination results or elevated prostate-specific antigen levels (age groups: 41-50 year

73 s, the assay was superior to the analysis of prostate-specific antigen levels (area under the curve:

74 undance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patie

75 ed to delineate the relationship between the prostate-specific antigen levels and the diffusion param

76 obtained by applying mathematical models to prostate-specific antigen levels as the representation o

77 stage cT1-2, localized prostate cancer, with prostate-specific antigen levels less than 50 ng/mL, and

78 only (n = 16), after surgery and with serum prostate-specific antigen levels lower than 0.2 ng/mL (n

79 A decrease in prostate-specific antigen levels was noted in 45 of 56 p

80 ematologic status, renal function, and serum prostate-specific antigen levels were documented before

81 detection rates even in the presence of low prostate-specific antigen levels.

82 than or equal to 3 + 4 in men with elevated prostate-specific antigen levels.

83 than or equal to 3 + 4 in men with elevated prostate-specific antigen levels.

84 ntermediate risk prostate cancer (Gleason 7, prostate-specific antigen < 10 ng/mL or Gleason 6, prost

85 n score <= 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly alloc

86 PSMA) PET/CT in the detection of early CRPC (prostate-specific antigen <= 3 ng/mL).

87 Following detection of high levels of serum prostate-specific antigen, many men are advised to have

88 All patients had a rising level of prostate-specific antigen (mean +/- SD, 13.5 +/- 11.5) a

89 llowed (ie, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal

90 ical failure was defined with the use of the prostate-specific antigen nadir + 2-ng/mL definition), f

91 herapy) was 1% +/- 40%, excluding 1 patient (prostate-specific antigen-negative) from the population.

92 hanges occurred most often for patients with prostate-specific antigen of 0.5 to less than 2.0 ng/mL

93 No prostate-specific antigen or RECIST responses were seen

94 associations included the following: SUV and prostate-specific antigen percentage change at 6 mo (P =

95 risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline

96 The radiosensitivity for the prostate-specific antigen-positive patients was determin

97 nts in all key secondary end points: time to prostate-specific antigen progression (HR, 0.19; 95% CI,

98 free survival (cPFS) end point that included prostate-specific antigen progression events.

99 ily for asymptomatic, local, or biochemical (prostate-specific antigen) progression.

100 Presence of prostate-specific antigen (proxy for recent sex) and bei

101 rogen receptor and its target gene products, prostate specific antigen (PSA) and ETS-related gene (ER

102 range) was decorated with antibodies against prostate specific antigen (PSA) and prostate specific me

103 ing 8-hydroxy-2'-deoxyguanosine (8-OHdG) and prostate specific antigen (PSA) as representatives for s

104 ta-MIP) with FETs for sensitive detection of prostate specific antigen (PSA) at clinically relevant c

105 urement of prostate volume, uroflowmetry and prostate specific antigen (PSA) at one, 3 and 6 months a

106 was designed to utilize for the detection of prostate specific antigen (PSA) based on three different

107 s method, post-prostatectomy surveillance of prostate specific antigen (PSA) can be achieved with a d

108 n in human serum of as low as 25 pg/ml total prostate specific antigen (PSA) during 30-min assay.

109 We demonstrate how prostate specific antigen (PSA) expression varies over s

110 exhibited real-time reversible detection of prostate specific antigen (PSA) from 1 to 1,000 nM in 10

111 trated label-free and real-time detection of prostate specific antigen (PSA) in human serum using sil

112 ochemical aptasensor to detect the biomarker prostate specific antigen (PSA) in serum.

113 Prostate specific antigen (PSA) is a glycoprotein which

114 The diagnostic specificity of prostate specific antigen (PSA) is limited.

115 Prostate specific antigen (PSA) is the common biomarker

116 Patients were stratified as prostate specific antigen (PSA) progressive versus respo

117 Highly sensitive and label free detection of prostate specific antigen (PSA) still remains a challeng

118 The development of the prostate specific antigen (PSA) test, and a continuing d

119 Prostate specific antigen (PSA) tests and digital rectal

120 States Food and Drug Administration) is the prostate specific antigen (PSA) that is detected by conv

121 unting single molecules of the cancer marker prostate specific antigen (PSA) using photon-upconversio

122 detection of recurrent disease at low serum prostate specific antigen (PSA) values below 0.5 ng/mL c

123 ed DNA aptamer with established affinity for prostate specific antigen (PSA) was complexed with PSA p

124 Prostate cancer biomarker proteins, prostate specific antigen (PSA), prostate specific membr

125 Prostate cancer biomarkers prostate specific antigen (PSA), vascular endothelial gr

126 ances were implemented for glycoprofiling of prostate specific antigen (PSA), what can be applied for

127 de (rGO) thin films as transducers to detect prostate specific antigens (PSA) in a physiological buff

128 tal of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) >/= 10 ng/mL or Gleason

129 Eligible men had an elevated level of prostate-specific antigen (PSA) (>0.2 ng/mL) and high-ri

130 All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL;

131 ters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT.

132 e radiotherapy (SRT) for men with detectable prostate-specific antigen (PSA) after radical prostatect

133 referred for PSMA PET with a rising level of prostate-specific antigen (PSA) after RP.

134 on the therapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase

135 Serum prostate-specific antigen (PSA) and Expanded Prostate In

136 ncluding high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, a

137 We determine kon and koff for prostate-specific antigen (PSA) and make a comparison to

138 ced prostate MR imaging in men with elevated prostate-specific antigen (PSA) and negative transrectal

139 urpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in

140 ing tool, to diagnose prostate cancer (PCa): prostate-specific antigen (PSA) and spondin-2 (SPON2).

141 ndwich immune complexes of the cancer marker prostate-specific antigen (PSA) are detected and counted

142 glycan structure of the glycoproteins, with prostate-specific antigen (PSA) as a model target.

143 The prostate-specific antigen (PSA) assays currently employe

144 ent of the gold content allowed detection of Prostate-Specific Antigen (PSA) at the low attog mL(-1)

145 se with biochemical recurrence stratified by prostate-specific antigen (PSA) at the time of imaging.

146 rvation policy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression.

147 pplied stratification systems use presenting prostate-specific antigen (PSA) concentration, biopsy Gl

148 r radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations (<2.0 ng/

149 ease-specific quality of life, health worry, prostate-specific antigen (PSA) concern, and outlook on

150 Men who did not achieve >/= 30% prostate-specific antigen (PSA) decline by cycle 4 (C4)

151 A sensitive prostate-specific antigen (PSA) detection method using a

152 ith castration-sensitive prostate cancer and prostate-specific antigen (PSA) doubling time (DT) of le

153 The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less th

154 We simulate prostate-specific antigen (PSA) dynamics, with enrichmen

155 noma, with strong androgen receptor (AR) and prostate-specific antigen (PSA) expression.

156 gen) PET/CT is increasingly used in men with prostate-specific antigen (PSA) failure after radical pr

157 controlled trials (RCTs) relating to reduced prostate-specific antigen (PSA) failure, yet whether thi

158 combinations of histopathology, imaging, or prostate-specific antigen (PSA) follow up, defined as co

159 Surveillance was performed with prostate-specific antigen (PSA) follow-up every 3 months

160 ening and quantitatively precise analysis of prostate-specific antigen (PSA) in 10 min from merely on

161 For the measurements of prostate-specific antigen (PSA) in 50% serum using the p

162 ascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early

163 e of nanopore blockade sensing system, where prostate-specific antigen (PSA) is used as a model analy

164 Prostate-specific antigen (PSA) is widely used to monito

165 , renal scintigraphy, clinical data, and the prostate-specific antigen (PSA) level at baseline and 8

166 to determine the relationship between serum prostate-specific antigen (PSA) level categories (<5, 5-

167 deprivation therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4.0 ng

168 Prostate-specific antigen (PSA) level in midlife predict

169 e >=70 years), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL

170 SMA-targeted radiotracers in patients with a prostate-specific antigen (PSA) level less than 2 ng/mL.

171 rrent prostate cancer in 60% of cases with a prostate-specific antigen (PSA) level of >=0.4 to <0.5,

172 early stage of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/

173 The median prostate-specific antigen (PSA) level was 1.2 ng/mL (ran

174 His prostate-specific antigen (PSA) level was 7.1 ng/mL.

175 The 24-hour post-PAE prostate-specific antigen (PSA) level was registered in

176 ogression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progress

177 ADT, with complete datasets for RT, surgery, prostate-specific antigen (PSA) level, Gleason score, an

178 rior negative biopsy findings with increased prostate-specific antigen (PSA) level, or (c) had a prio

179 med recurrence was correlated with patients' prostate-specific antigen (PSA) level, primary Gleason s

180 fine patient characteristics, including age, prostate-specific antigen (PSA) level, PSA density, race

181 ed by a persistently or recurrently elevated prostate-specific antigen (PSA) level.

182 ets in the blood of 72 asymptomatic men with Prostate-Specific Antigen (PSA) levels < 20 ng ml(-1), o

183 olled in an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean, 3.43 ng/mL

184 led onto an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean:3.43 ng/mL,

185 ity rate of 85%, which increased with higher prostate-specific antigen (PSA) levels (ng/mL): 50% (PSA

186 Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were

187 (68)Ga-PSMA I&T PET/CT because of increasing prostate-specific antigen (PSA) levels after radical pro

188 A significant proportion of men with rising prostate-specific antigen (PSA) levels after radical pro

189 interrogated irrespective of Gleason grade, prostate-specific antigen (PSA) levels and pathological

190 Joint statistical model of longitudinal prostate-specific antigen (PSA) levels and risks for bio

191 Prostate-specific antigen (PSA) levels have been used fo

192 identify genes associated with pre-operative prostate-specific antigen (PSA) levels in patients.

193 ay with biopsy outcomes in 499 patients with prostate-specific antigen (PSA) levels of 2 to 20 ng/mL.

194 ty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 n

195 stant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking andr

196 The survival of patients with different prostate-specific antigen (PSA) levels, Gleason scores,

197 Criteria in Solid Tumors 1.1), a decrease in prostate-specific antigen (PSA) of 50% or more (PSA50) f

198 One hundred eighteen patients with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range, 2.2

199 ET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvag

200 ry definitive radiotherapy, 51% (88/172) for prostate-specific antigen (PSA) persistence, and 36% (62

201 e (PET1), week 13 (PET2), and at the time of prostate-specific antigen (PSA) progression, standard ra

202 Prostate-specific antigen (PSA) progression-free surviva

203 ent continued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise,

204 combination strongly associates with reduced prostate-specific antigen (PSA) recurrence-free survival

205 w and by investigators) and locally assessed prostate-specific antigen (PSA) response (>= 50% decreas

206 Endpoints included prostate-specific antigen (PSA) response (Prostate Cance

207 sorbed dose was 11.55 Gy and correlated with prostate-specific antigen (PSA) response at 12 wk.

208 ta, week 13 circulating tumor cell (CTC) and prostate-specific antigen (PSA) response end points in f

209 Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and w

210 radiographic progression-free survival, and prostate-specific antigen (PSA) response rate.

211 , 2.8-3.7 GBq); afterward, safety lab tests, prostate-specific antigen (PSA) response, and clinical f

212 Main Outcomes and Measures: Prostate-specific antigen (PSA) response, time receiving

213 R-V7-negative disease associated with better prostate-specific antigen (PSA) responses (100% vs. 54%,

214 We examined >/= 50% prostate-specific antigen (PSA) responses, PSA progressi

215 progression on enzalutamide with a continued prostate-specific antigen (PSA) rise after enzalutamide

216 2012, US guidelines have recommended against prostate-specific antigen (PSA) screening for prostate c

217 Prostate-specific antigen (PSA) screening for prostate c

218 A serum prostate-specific antigen (PSA) test was 12.4 ng/mL.

219 sk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be

220 ents for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertai

221 -negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or

222 The median prostate-specific antigen (PSA) value was 1.0 ng/mL (mea

223 Interestingly, on considering prostate-specific antigen (PSA) value, (64)CuCl2 PET/CT

224 uperior to standard-of-care imaging at serum prostate-specific antigen (PSA) values low enough to aff

225 Afterward, data were compared with current prostate-specific antigen (PSA) values, Gleason score (G

226 /CT remains challenging in patients with low prostate-specific antigen (PSA) values.

227 Prostate-specific antigen (PSA) was determined every 4 w

228 Prostate-specific antigen (PSA) was measured for respons

229 Serial prostate-specific antigen (PSA) was obtained for PSA res

230 Here, prostate-specific antigen (PSA) was selected as a templa

231 Testosterone and prostate-specific antigen (PSA) were measured at baselin

232 urinary flow rate, postvoid residual volume, prostate-specific antigen (PSA), and prostate volume wer

233 g tumor cells (CTCs), bone biomarkers, serum prostate-specific antigen (PSA), and symptomatic skeleta

234 cer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as

235 rker for prostate adenocarcinoma (PC), serum prostate-specific antigen (PSA), greatly overestimates P

236 ival outcomes was constructed combining age, prostate-specific antigen (PSA), histological grade, bio

237 he transcription of AR target genes, such as prostate-specific antigen (PSA), is also lowered in the

238 er scheduled for PSMA RLT were evaluated for prostate-specific antigen (PSA), lactate dehydrogenase (

239 Event-free survival (EFS), an earlier prostate-specific antigen (PSA)-based composite end poin

240 supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men a

241 To examine whether the use of prostate-specific antigen (PSA)-based screening in patie

242 The goal of prostate-specific antigen (PSA)-based screening is to id

243 The prostate-specific antigen (PSA)-stratified detection rat

244 ection of a prostate cancer's biomarker, the prostate-specific antigen (PSA).

245 y kallikrein-related peptidase 3 (KLK3), aka prostate-specific antigen (PSA).

246 n of rabbit immunoglobulin G (IgG) and human-prostate-specific antigen (PSA).

247 e covariates: alkaline phosphatase (ALP) and prostate-specific antigen (PSA).

248 ere evaluable for the primary end point of a prostate-specific antigen (PSA)50 response (PSA decline

249 r growth can be estimated by measuring serum prostate-specific antigen (PSA, a PCa biomarker in blood

250 evidence of either biochemical progression (prostate-specific antigen [PSA] >=0.4 ng/mL and rising a

251 orable-risk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] <=20 ng/mL, and Grade Gr

252 e cancer (T1 to 2a, Gleason score </= 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to

253 e the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5

254 tence (BCP; that is, persistently measurable prostate-specific antigen [PSA] values after robot-assis

255 ) (clinical stage, T1c; Gleason score, </=6; prostate-specific antigen [PSA], <10 ng/mL; PSA density

256 , low- to intermediate-risk prostate cancer (prostate-specific antigen [PSA], <=15 ng/mL; Gleason sco

257 th documented biochemical recurrence (median prostate-specific antigen [PSA], 2.5 ng/mL; range, 0.21-

258 ssion was correlated with Gleason scores and prostate-specific antigen recurrence.

259 tients (mean age, 68 y; range, 44-87 y) with prostate-specific antigen relapse (mean prostate-specifi

260 cause screening for prostate cancer based on prostate-specific antigen remains controversial due to t

261 .001); proportion of patients with a >/= 50% prostate-specific antigen response (81% v 31%; P < .001)

262 Prostate-specific antigen response and hematologic toxic

263 The primary endpoint was a prostate-specific antigen response in relation to baseli

264 ath, 0.52; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and

265 reasonable response, mainly as defined by a prostate-specific antigen response of more than 50%, com

266 Main Outcomes and Measures: Prostate-specific antigen response rate (decline >/=50%

267 Prostate-specific antigen response rate to enzalutamide

268 Exploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab

269 d increases in progression-free survival and prostate-specific antigen response rates suggest antitum

270 The initial prostate-specific antigen response showed no correlation

271 checked every 2 wk by laboratory tests, the prostate-specific antigen response was checked every 4 w

272 ith AR-V7-positive mCRPC had fewer confirmed prostate-specific antigen responses (0% to 11%) or soft

273 Prostate-specific antigen responses to ipilimumab were a

274 Overall survival (OS) and prostate-specific antigen responses were secondary end p

275 rho = 0.64; PSMA expression, rho = 0.47; and prostate-specific antigen, rho = 0.52).

276 BCR was defined as 2 consecutive prostate-specific antigen rises of at least 0.2 ng/mL.

277 Studies demonstrate that use of prostate-specific antigen screening decreased significan

278 s Task Force (USPSTF) recommendation against prostate-specific antigen screening in 2012.

279 commendation against routine population-wide prostate-specific antigen screening.

280 nding on presentation of symptoms, including prostate-specific antigen, serum creatinine, urine cytol

281 KLK3, the AR-responsive gene that encodes prostate specific antigen, shows the greatest variabilit

282 hemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy

283 Prostate-specific antigen testing every 4 to 6 months is

284 Active surveillance protocols should include prostate-specific antigen testing, digital rectal examin

285 n of DIO2 was shown to supress expression of prostate specific antigen, the cardinal clinical biomark

286 and were inversely correlated with levels of prostate-specific antigen, the main prognostic factor in

287 onal level) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stag

288 s, 11 (18%) demonstrated a >= 50% decline in prostate-specific antigen; two (6%) of 36 with measurabl

289 Men with high serum prostate specific antigen usually undergo transrectal ul

290 ficant correlations were found between serum prostate-specific antigen value and both PSMA-TV (r = 0.

291 The patients had a median prescan prostate-specific antigen value of 12.2 ng/mL (range, 1.

292 years +/- 8 (standard deviation); the median prostate-specific antigen value was 6.3 ng/mL.

293 61 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-

294 Patients with low prostate-specific antigen values (<0.5 ng/mL) also demon

295 0.76 and 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, res

296 nts who had undergone PSMA PET for CRPC, had prostate-specific antigen values of at least 1 ng/mL, an

297 Median prostate-specific antigen was 15.1 ng/mL; 53% had a Glea

298 ously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184).

299 in this Perspective explore the detection of prostate-specific antigen which enables a comparison bet

300 ode signal outputs, the PT-Disk can quantify prostate specific antigen with limits of detection of 1.